JP2019500876A5 - - Google Patents

Download PDF

Info

Publication number
JP2019500876A5
JP2019500876A5 JP2018535126A JP2018535126A JP2019500876A5 JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5 JP 2018535126 A JP2018535126 A JP 2018535126A JP 2018535126 A JP2018535126 A JP 2018535126A JP 2019500876 A5 JP2019500876 A5 JP 2019500876A5
Authority
JP
Japan
Prior art keywords
culture
glycan
monoclonal antibody
man
cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2018535126A
Other languages
English (en)
Japanese (ja)
Other versions
JP6674028B2 (ja
JP2019500876A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/012349 external-priority patent/WO2017120347A1/en
Publication of JP2019500876A publication Critical patent/JP2019500876A/ja
Publication of JP2019500876A5 publication Critical patent/JP2019500876A5/ja
Application granted granted Critical
Publication of JP6674028B2 publication Critical patent/JP6674028B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2018535126A 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節 Active JP6674028B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201662275384P 2016-01-06 2016-01-06
US62/275,384 2016-01-06
PCT/US2017/012349 WO2017120347A1 (en) 2016-01-06 2017-01-05 Modulation of afucosylated species in a monoclonal antibody composition

Publications (3)

Publication Number Publication Date
JP2019500876A JP2019500876A (ja) 2019-01-17
JP2019500876A5 true JP2019500876A5 (enExample) 2020-02-13
JP6674028B2 JP6674028B2 (ja) 2020-04-01

Family

ID=57944513

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018535126A Active JP6674028B2 (ja) 2016-01-06 2017-01-05 モノクローナル抗体組成物中のアフコシル化種の調節

Country Status (8)

Country Link
US (1) US20190161543A1 (enExample)
EP (1) EP3400241B1 (enExample)
JP (1) JP6674028B2 (enExample)
CN (1) CN109153716A (enExample)
AU (1) AU2017206006B2 (enExample)
CA (1) CA3010598A1 (enExample)
MX (1) MX2018008447A (enExample)
WO (1) WO2017120347A1 (enExample)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10376582B2 (en) 2013-10-16 2019-08-13 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
WO2016118707A1 (en) 2015-01-21 2016-07-28 Oncobiologics, Inc. Modulation of charge variants in a monoclonal antibody composition
AU2017213775A1 (en) 2016-02-03 2018-08-16 Outlook Therapeutics, Inc. Buffer formulations for enhanced antibody stability
SG11202009216YA (en) * 2018-03-26 2020-10-29 Amgen Inc Total afucosylated glycoforms of antibodies produced in cell culture
HU231514B1 (hu) 2018-11-07 2024-07-28 Richter Gedeon Nyrt. Sejttenyészetben előállított rekombináns glikoprotein glikozilációs mintázatának megváltoztatására szolgáló módszer
JP2022514299A (ja) * 2018-12-19 2022-02-10 シージェン インコーポレイテッド 抗体の制御されたフコシル化
WO2021066772A1 (en) * 2019-10-01 2021-04-08 Arven Ilac Sanayi Ve Ticaret Anonim Sirketi Cell culture medium for reducing fucosylation and basic variants in the production of antibodies

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6090382A (en) 1996-02-09 2000-07-18 Basf Aktiengesellschaft Human antibodies that bind human TNFα
US8227241B2 (en) 2004-03-12 2012-07-24 Unigene Laboratories, Inc. Bacterial host cell for the direct expression of peptides
JP5442251B2 (ja) 2005-05-26 2014-03-12 サイトス バイオテクノロジー アーゲー 拡張可能な発酵方法
US7846724B2 (en) 2006-04-11 2010-12-07 Hoffmann-La Roche Inc. Method for selecting CHO cell for production of glycosylated antibodies
CN102076865B (zh) * 2008-05-02 2016-03-16 西雅图基因公司 用于制造核心岩藻糖基化降低的抗体和抗体衍生物的方法和组合物
PL2438171T3 (pl) * 2009-06-02 2015-04-30 Regeneron Pharma Komórki z niedoborem fukozylacji
WO2010141855A1 (en) * 2009-06-05 2010-12-09 Momenta Pharmaceuticals, Inc. Methods of modulating fucosylation of glycoproteins
US20120258496A1 (en) * 2010-09-27 2012-10-11 Boehringer Ingelheim International Gmbh Production of low fucose antibodies in h4-ii-e rat cells
WO2013114165A1 (en) * 2012-01-30 2013-08-08 Dr Reddy's Laboratories Limited Process of obtaining glycoprotein composition with increased afucosylation content
NO2760138T3 (enExample) * 2012-10-01 2018-08-04
WO2015140700A1 (en) * 2014-03-19 2015-09-24 Dr. Reddy's Laboratories Limited Cell culture process
MX2018004831A (es) * 2015-11-02 2018-08-01 Genentech Inc Metodos para confeccionar formas fucosiladas y afucosiladas de una proteina.

Similar Documents

Publication Publication Date Title
JP2019500876A5 (enExample)
Carrillo-Cocom et al. Amino acid consumption in naive and recombinant CHO cell cultures: producers of a monoclonal antibody
JP6982578B2 (ja) 細胞培養培地
Padawer et al. Case study: an accelerated 8‐day monoclonal antibody production process based on high seeding densities
BRPI0514680A (pt) produção de anticorpos anti-amilóide beta
RU2642285C1 (ru) Способ получения целевого антитела с модулированным галактозилированием (варианты) и способ модулирования галактозилирования целевого антитела (варианты) путем оптимизации культуральной среды
RU2008152449A (ru) Получение гликопротеинов
IL201395A (en) Multi-clonal cell lines and methods for generating multi-clonal cell lines
NZ701825A (en) Heterodimeric antibody fc-containing proteins and methods for production thereof
JP2019505164A5 (enExample)
UA120048C2 (uk) Антигензв'язуючий фрагмент антитіла, який специфічно зв'язується з рецептором інсуліноподібного фактора росту 1 (igf1r)
JP2016513478A5 (enExample)
MX2018008447A (es) Modulacion de especies afucosilados en una composicion de anticuerpo monoclonal.
JP2016523910A5 (enExample)
IL313983A (en) Fully fucose-free glycoforms of antibodies are produced in cell culture
CN104560882A (zh) 一种降低酸性变体含量的cho细胞培养工艺
Amribt et al. Optimization and robustness analysis of hybridoma cell fed-batch cultures using the overflow metabolism model
IL307155B1 (en) Antibodies with modulated glycan profiles
GB0321100D0 (en) Biological products
Lin et al. Enhancing the yield and activity of defucosylated antibody produced by CHO-K1 cells using Cas13d-mediated multiplex gene targeting
Lee et al. Effect of hypoosmotic pressure on cell growth and antibody production in recombinant Chinese hamster ovary cell culture
Shi et al. Controlled growth of Chinese hamster ovary cells and high expression of antibody-IL-2 fusion proteins by temperature manipulation
Mahboudi et al. The role of different supplements in expression level of monoclonal antibody against human CD20
Fan et al. Effect of culture temperature on TNFR-Fc productivity in recombinant glutamine synthetase-chinese hamster ovary cells
Clincke et al. Effect of iron sources on the glycosylation macroheterogeneity of human recombinant IFN-γ produced by CHO cells during batch processes